The PD-L1 and OX40 bispecific antibody IBI327 induces immune activation and improves cancer immunotherapy

被引：0
|
作者：
Chen, Bingliang [1 ]
Kuang, Zhihui [1 ]
Li, Yiming [1 ]
Zhou, Shuaixiang [1 ]
Wu, Zhihai [1 ]
Wu, Min [1 ]
Yu, Michael [1 ]
Liu, Junjian [1 ]
机构：
[1] Innovent Biol Suzhou Co Ltd, Suzhou, Peoples R China
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-2268
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2268
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment
    Kuang, Zhihui
    Pu, Pu
    Wu, Min
    Wu, Zhihai
    Wang, Li
    Li, Yiming
    Zhang, Shaofei
    Jing, Hua
    Wu, Weiwei
    Chen, Bingliang
    Liu, Junjian
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (12) : 2564 - 2574
  • [2] A novel immunostimulatory OX40/PD-L1 bivalent bispecific antibody (MEDI1109) for the treatment of patients with cancer
    Oberst, Michael D.
    Kasturirangan, Srinath
    Sachs, Clifford
    Auge, Catherine
    Moynihan, James
    Rothstein, Raymond
    Hair, James
    Neal, Francis
    Mamidi, Srinivas
    Hanabuchi, Shino
    Watkins, Amanda
    Zheng, Yanan
    Rosenthal, Kim
    Freeman, Daniel J.
    Hammond, Scott
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
    Li, Tianye
    Wang, Xinrun
    Niu, Mengke
    Wang, Mingli
    Zhou, Jianwei
    Wu, Kongming
    Yi, Ming
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [4] Differential expression of immune checkpoints (OX40/OX40L and PD-1/PD-L1) in decidua of unexplained recurrent spontaneous abortion women
    Qian, Chenyue
    Pan, Chenhuan
    Liu, Juanjuan
    Wu, Lijuan
    Pan, Jie
    Liu, Cuiping
    Zhang, Hong
    HUMAN IMMUNOLOGY, 2024, 85 (01)
  • [5] Urinary Cell Levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and Acute Rejection of Human Renal Allografts
    Afaneh, Cheguevara
    Muthukumar, Thangamani
    Lubetzky, Michelle
    Ding, Ruchuang
    Snopkowski, Catherine
    Sharma, Vijay K.
    Seshan, Surya
    Dadhania, Darshana
    Schwartz, Joseph E.
    Suthanthiran, Manikkam
    TRANSPLANTATION, 2010, 90 (12) : 1381 - 1387
  • [6] Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection
    Li Tao
    Ma Rui
    Zhu Jiye
    Wang Fushun
    Huang Lei
    Leng Xisheng
    中华医学杂志（英文版）, 2014, (14) : 2686 - 2692
  • [7] Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection
    Li Tao
    Ma Rui
    Zhu Jiye
    Wang Fushun
    Huang Lei
    Leng Xisheng
    CHINESE MEDICAL JOURNAL, 2014, 127 (14) : 2686 - 2692
  • [8] A Novel Designed Anti-PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity
    Li, Baocun
    Gong, Shiyong
    Zhang, Nianying
    Shi, Beilei
    Lv, Zhou
    Zhang, Yu
    Gaowa, Naren
    Dong, Liqin
    Wu, Danqing
    Wu, Jianfu
    Liu, Fan
    Zhang, Rui
    Behzadigohar, Ramin
    Ganju, Vinod
    Wu, Chengbin
    Wu, Xuan
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (03) : 317 - 330
  • [9] Effect of cancer immunotherapy with CD39/PD-L1 bispecific antibody OriA631-b
    Li, Xiaopei
    Zhang, Yuchen
    Yang, Ze
    Deng, Qi
    Wang, Huajing
    Zhu, Haiyan
    Lu, Ligong
    Li, Xian-Yang
    Qu, Ryan
    He, Xiaowen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer
    Ma, Ying
    Li, Jun
    Wang, Huamin
    Chiu, Yulun
    Kingsley, Charles, V
    Fry, David
    Delaney, Samantha N.
    Wei, Spencer C.
    Zhang, Jianhua
    Maitra, Anirban
    Yee, Cassian
    GASTROENTEROLOGY, 2020, 159 (01) : 306 - +
12345